Oncolytics Biotech Will Present Data from Pilot Study at 57th American Society of Hematology Annual Meeting

Oncolytics Biotech (TSE:ONC) has announced that it will present data from a pilot study at the 57th American Society of Hematology (ASH) Annual Meeting.
According to the press release:

Dr. D.W. Sborov and colleagues made a poster presentation at the 57th American Society of Hematology (ASH) Annual Meeting. The poster presentation, titled “REOLYSINtrademark Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients,” discloses updated findings from a pilot study (NCI-9603) in patients with relapsed or refractory multiple myeloma treated using the combination of carfilzomib and Oncolytics Biotech Inc.’s Reolysin. The ASH Annual Meeting runs from December 5th to 8th in Orlando, FL.
Highlights of the data presented include:All seven patients treated at the full clinical dose had a clinical response. Patients treated at the full clinical dose (dose level 1) had a deeper and more prolonged response than those treated at dose level minus 1. Of the 12 total patients treated, 11 had a decrease in dominant monoclonal protein during treatment (used to measure clinical response), including all seven patients treated at the full clinical dose; The combination of carfilzomib and REOLYSINtrademark produced a significant (p=0.005) increase in caspase-3, a marker associated with apoptotic (programmed) cell death, but to a higher degree in those patients treated at dose level 1; and The treatment combination was associated with an increased infiltration of CD8+ T-cells and the significant (p=0.005) upregulation of PD-L1, suggesting that the addition of a PD-1 or PD-L1 inhibitor may further optimize the treatment regimen.
“These findings are compelling as we continue to see a strong clinical benefit rate in this difficult to treat cancer, and clear evidence of a dose response, with patients at the higher dosing level seeing improved outcomes. We plan on testing higher dosage levels to determine the extent of this improvement,” said Dr. Matt Coffey, Chief Operating Officer of Oncolytics. “We recently announced a second study in multiple myeloma examining REOLYSINtrademark together with bortezomib, with the goal of identifying the best standard of care combination to advance into later stage clinical testing.”

 
Click here to read the full press release.